Brief: Repare Therapeutics Inc Entered Into A Collaboration And License Agreement With Hoffmann-La Roche Inc. And F. Hoffmann-La Roche Ltd

Repare Therapeutics

01/06/2022 21:18

June 1 (Reuters) - Repare Therapeutics Inc  RPTX.O :
    * REPARE THERAPEUTICS INC -  ON JUNE 1, ENTERED INTO A
COLLABORATION AND LICENSE AGREEMENT WITH HOFFMANN-LA ROCHE INC.
AND F. HOFFMANN-LA ROCHE LTD
    * REPARE THERAPEUTICS - AGREEMENT REGARDING DEVELOPMENT AND
COMMERCIALIZATION OF CO'S PRODUCT CANDIDATE CAMONSERTIB AND
SPECIFIED OTHER ATR INHIBITORS
    * REPARE THERAPEUTICS INC - WILL GRANT ROCHE A WORLDWIDE,
EXCLUSIVE, SUBLICENSABLE LICENSE TO DEVELOP, MANUFACTURE, AND
COMMERCIALIZE LICENSED PRODUCTS
    * REPARE THERAPEUTICS INC - WILL RETAIN AN OPTION UNDER
AGREEMENT
TO ENTER INTO A U.S. CO-DEVELOPMENT AND PROFIT SHARE ARRANGEMENT
WITH ROCHE
    * REPARE THERAPEUTICS INC - ALSO RETAINED RIGHT TO CONDUCT
SPECIFIED CLINICAL TRIALS OF CAMONSERTIB IN COMBINATION WITH
COMPANY'S PKMYT1 COMPOUND
    * REPARE THERAPEUTICS INC - ROCHE HAS AGREED TO PAY COMPANY
AN
UPFRONT PAYMENT OF $125 MILLION
    * REPARE THERAPEUTICS -  ROCHE HAS AGREED TO PAY UP TO
$1.172
BILLION UPON ACHIEVING SPECIFIED CLINICAL REGULATORY, COMMERCIAL
AND SALES MILESTONE EVENTS
    * REPARE THERAPEUTICS -  WILL ALSO BE ENTITLED TO RECEIVE
TIERED
ROYALTIES (RANGING FROM HIGH-SINGLE-DIGITS TO HIGH-TEENS) ON
SALES OF LICENSED PRODUCTS

Further company coverage:  RPTX.O